Immunotherapy Shows Promise for Treatment-Resistant Depression in Pilot Trial
Similar Articles
Common Asthma Drug Shows Promise Against Multiple Cancer Types in Early Research
New Study Identifies Distinct Brain Cell Changes in Depression
Nasal Spray Therapy Shows Promise in Reducing Brain Inflammation and Restoring Memory
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
Immunotherapy Shows Promise as Pre-Surgery Treatment for Specific Bowel Cancer
A University of Bristol-led pilot trial found that the anti-inflammatory drug tocilizumab may help patients with treatment-resistant depression. In the small study, 54% of participants receiving the drug achieved remission, compared to 31% on a placebo. The findings support further investigation into inflammation as a biological driver of depression.
Facts First
- 54% of participants on tocilizumab achieved depression remission in a four-week pilot trial, compared to 31% on placebo.
- The trial targeted patients with treatment-resistant depression and signs of low-grade inflammation.
- The Number Needed to Treat (NNT) for tocilizumab was 5, compared to an NNT of approximately 7 for standard SSRIs.
- The study builds on research linking inflammation and the protein Interleukin 6 (IL-6) to depression.
- A larger phase III randomized controlled trial is planned to assess broader use of immunotherapy for depression.
What Happened
A pilot clinical trial led by the University of Bristol tested the anti-inflammatory drug tocilizumab in 30 patients with moderate-to-severe, treatment-resistant depression and signs of low-grade inflammation. The four-week randomized controlled trial found that 54% of participants receiving tocilizumab achieved depression remission, compared to 31% of those receiving a saltwater placebo. The study, published in JAMA Psychiatry, was funded by Wellcome and recruited participants through the University of Cambridge and the Cambridgeshire and Peterborough NHS Foundation Trust.
Why this Matters to You
If you or someone you know struggles with depression that hasn't improved with standard antidepressants, this research opens a new potential pathway for treatment. The findings suggest that for a subset of patients where inflammation is a factor, targeting the immune system could be more effective than targeting brain chemicals alone. This could lead to more personalized and effective treatment options in the future.
What's Next
The research team has planned a phase III randomized controlled trial to determine if immunotherapy should be prescribed for depression more broadly. This larger study will be crucial for confirming the pilot results and understanding which patients are most likely to benefit from this approach.